Cytochrome P450 and ABCB1 genetics: Association with quetiapine and norquetiapine plasma and cerebrospinal fluid concentrations and with clinical response in patients suffering from schizophrenia. A pilot study

Journal of Psychopharmacology

Volumn 25, Issue 7, 2011, Pages 896-907

  Nikisch, Georg ^a   Baumann, Pierre ^b   Oneda, Beatrice ^b   Kiessling, Bernhard ^a   Weisser, Heike ^a   Mathé, Aleksander A ^c   Yoshitake, Takashi ^d   Kehr, Jan ^d   Wiedemann, Georg ^a   Eap, Chin B ^b,e  

^a KLINIKUM FULDA   (Germany)

^b Hopital de Cery   (Switzerland)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

^e UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

ABCB1 genetics; cytochrome P450; norquetiapine; P glycoprotein; quetiapine; schizophrenia

Indexed keywords

ARIPIPRAZOLE; CYTOCHROME P450; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 3A7; CYTOSINE; DRUG METABOLITE; GUANINE; MULTIDRUG RESISTANCE PROTEIN 1; NORQUETIAPINE; OLANZAPINE; QUETIAPINE; RISPERIDONE; THYMINE; UNCLASSIFIED DRUG;

ABCB1 GENE; ADULT; AMINO ACID SUBSTITUTION; ARTICLE; ASTHENIA; BODY MASS; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONCENTRATION LOSS; CYP GENE; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DOSE INCREASE; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EJACULATION DISORDER; EMOTIONAL DISORDER; ERECTILE DYSFUNCTION; FEMALE; GENE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HYPERGLYCEMIA; IMPULSIVENESS; LIBIDO DISORDER; MALE; OPEN STUDY; ORGASM DISORDER; PILOT STUDY; POSITIVE AND NEGATIVE SYNDROME SCALE; PREDICTION; PRIORITY JOURNAL; SALIVATION; SCHIZOPHRENIA; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SLEEP TIME; SOMNOLENCE; STEP WISE MULTIPLE REGRESSION; SWEATING; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; DIBENZOTHIAZEPINES; FEMALE; HUMANS; LINEAR MODELS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; P-GLYCOPROTEIN; PHARMACOGENETICS; PILOT PROJECTS; PSYCHIATRIC STATUS RATING SCALES; RISK ASSESSMENT; RISK FACTORS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79956197766     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881110389208     Document Type: Article

References (46)

1. Alenius M, Wadelius M, Marja-Liisa Dahl ML, Hartvig P, Lindström L, Hammarlund-Udenaes M. Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting. J Psychiatr Res. 2008 ; 42: 884-893
2. Practise guidelines for treatment of patients with schizophrenia, 2nd edn. Am J Psychiatry. 2004 ; 161: 1-56
3. Arranz MJ, De Leon J. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol Psychiatry. 2007 ; 12: 707-747 (Pubitemid 47172693)
4. Bagnall AM, Jones L, Ginnelly L, Lewis R, Glanville J, Gilbody S, et al. A systematic review of antipsychotic drugs in schizophrenia. Health Technol Assess. 2003 ; 7: 1-193
5. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005 ; 21: 263-265 (Pubitemid 40202029)
6. Basson BR, Kinon BJ, Taylor CC, Szymanski KA, Gilmore JA, Tollefson GD. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry. 2001 ; 62: 231-238 (Pubitemid 32428761)
7. Blanc O, Brousse G, Meary A, Leboyer M, Llorca PM. Pharmacogenetic of response efficacy to antipsychotics in schizophrenia: pharmacodynamic aspects. Review and implications for clinical research. Fundam Clin Pharmacol. 2010 ; 24: 139-160
8. Boulton DW, DeVane CL, Liston HL, Markowitz JS. In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci. 2002 ; 71: 163-169 (Pubitemid 34595435)
9. Bozina N, Kuzman MR, Medved V, Jovanovic N, Sertic J, Hotujac L. Associations between MDR1 gene polymorphisms and schizophrenia and therapeutic response to olanzapine in female schizophrenic patients. J Psychiatr Res. 2008 ; 42: 89-97 (Pubitemid 350061252)
10. Crettol S, Déglon JJ, Besson J, Croquette-Krokar M, Hämmig R, Gothuey I, et al. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther. 2006 ; 80: 668-681 (Pubitemid 44920225)
11. Crettol S, Venetz JP, Fontana M, Aubert JD, Pascual M, Eap CB. CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients. Ther Drug Monit. 2008 ; 30: 689-699
12. Davis PC, Bravo O, Gehrke M, Azumaya CT. Development and validation of an LC-MS/MS method for the determination of quetiapine and four related metabolites in human plasma. J Pharm Biomed Anal. 2010 ; 51: 1113-1119
13. De Lange E, Danhof M. Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting. Implications of the barriers between blood and brain. Clin Pharmacokinet. 2002 ; 41: 691-703 (Pubitemid 34948192)
14. DeVane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine-An atypical antipsychotic. Clin Pharmacokinet. 2001 ; 40: 509-522
15. Dobrinas M, Eap CB. Cytochrome P4503A pharmacogenetics. HIV PGX. 2007 ; 2: 1-5
16. Ebinger M, Uhr M. ABC drug transporter at the blood-brain barrier: effects on drug metabolism and drug response. Eur Arch Psychiatry Clin Neurosci. 2006 ; 256: 294-298 (Pubitemid 44285053)
17. Gefvert O, Bergström M, Långström B, Lundberg T, Lindström L, Yates R. Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. Psychopharmacology. 1998 ; 135: 119-126 (Pubitemid 28055494)
18. Gex-Fabry M, Eap CB, Oneda B, Gervasoni N, Aubry JM, Bondolfi G, et al. CYP2D6 and ABCB1 genetic variability: Influence on paroxetine plasma level and therapeutic response. Ther Drug Monit. 2008 ; 30: 474-482
19. Grimm SW, Richtand NM, Winter HR, Stams KR, Reele SB. Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. Br J Clin Pharmacol. 2006 ; 61: 58-69 (Pubitemid 43381238)
20. Guy W ECDEU Assessment Manual for Psychopharmacology Revised (Publication ADM 76-338). Rockville, MD: US Department of Health, Education, and Welfare ; 1976: 218-222.
21. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J, Johne A, et al. Functional polymorphism of the human multidrug-resistance gene: multiple sequence variations and correlations of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A. 2000 ; 97: 3473-3478 (Pubitemid 30183327)
22. Ishikawa T, Tsuji A, Inui K, Sai Y, Anzai N, Wada M, et al. The genetic polymorphism of drug transporters: functional analysis approaches. Pharmacogenomics. 2004 ; 5: 67-99 (Pubitemid 38088481)
23. Jensen NH, Rodriguiz RM, Caron MG, Wetsel WC, Rothman RB, Roth B. N-Desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology. 2008 ; 33: 2303-2312
24. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987 ; 13: 261-276 (Pubitemid 18039085)
25. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, et al. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science. 2007 ; 315: 525-528 (Pubitemid 46175758)
26. Kronig MH, Munne RA, Szymanski S, Safferman AZ, Pollack S, Cooper T, et al. Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. Am J Psychiatry. 1995 ; 152: 179-182
27. Lieberman JA, Koreen AR, Chakos M, Sheitman B, Woerner M, Alvir J, et al. Factors influencing treatment response and outcome of first episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. J Clin Psychiatry. 1996 ; 57: 5-9 (Pubitemid 26327751)
28. Ling V. Multidrug resistance: molecular mechanism and clinical relevance. Cancer Chemother Pharmacol. 1997 ; 40: 3-8
29. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987 ; 334: 1-100 (Pubitemid 17115352)
30. Loscher W, Potschka H. Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J Pharmacol Exp Ther. 2002 ; 301: 7-14 (Pubitemid 34250273)
31. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, et al. Passive permeability and P-glycoprotein mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 ; 303: 1029-1037 (Pubitemid 35424386)
32. Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther. 2004 ; 75: 13-33 (Pubitemid 38130115)
33. Mrazek DA Psychiatric Pharmacogenomics. Oxford, New York: Oxford University Press ; 2010 :
34. Nakamura T, Sakaeda T, Horinouchi M, Tamura T, Aoyama N, Schirakawa T, et al. Effect of the mutation (C3435T) et exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther. 2002 ; 71: 297-303 (Pubitemid 34311459)
35. Nasrallah HA, Tandon R. Efficacy, safety, and tolerability of quetiapine in patients with schizophrenia. J Clin Psychiatry. 2002 ; 63 (Suppl 13). 12-20 (Pubitemid 35471365)
36. Nikisch G, Eap CB, Baumann P. Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: a pilot study. Pharmacol Res. 2008 ; 58: 344-347
37. Schirmer M, Rosenberger A, Klein K, Kulle B, Toliat MR, Nürnberg P, et al. Sex-dependent genetic markers of CYP3A4 expression and activity in human liver microsomes. Pharmacogenomics. 2007 ; 8: 443-453 (Pubitemid 46746352)
38. Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry. 1997 ; 54: 549-557 (Pubitemid 27258553)
39. Uhr M, Grauer MT, Yassouridis A, Ebinger M. Blood-brain barrier penetration and pharmacokinetics of amitriptyline and its metabolites in p-glycoprotein (abcb1ab) knock-out mice and controls. J Psychiatr Res. 2007 ; 41: 179-188 (Pubitemid 44708204)
40. Uhr M, Tontsch A, Namendorf C, Ripke S, Lucae S, Ising M, et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron. 2008 ; 572: 203-209
41. Wang D, Johnson AD, Papp AC, Kroetz DE, Sadée W. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics. 2005 ; 15: 693-704 (Pubitemid 41345321)
42. Wang JS, Zhu HJ, Markowitz JS, Donovan JL, DeVane CL. Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology. 2006 ; 187: 415-423 (Pubitemid 44200513)
43. Winter HR, Earley WR, Hamer-Maansson JE, Davis PC, Smith MA. Steady-state pharmacokinetic, safety, and tolerability profiles of quetiapine, norquetiapine, and other quetiapine metabolites in pediatric and adult patients with psychotic disorders. J Child Adolesc Psychopharmacol. 2008 ; 18: 81-98 (Pubitemid 351311245)
44. Wittchen HU, Wunderlich U, Gruschwitz S, Zaudig M SKID-I. Strukturiertes Klinisches Interview für DSM.IV. Achse I: Psychische Störungen. Göttingen, Germany: Hofgrefe ; 1997 :
45. Xing Q, Gao R, Li H, Feng G, Xu M, Duan S, et al. Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients. Pharmacogenomics. 2006 ; 7: 987-993 (Pubitemid 44644778)
46. Yasui-Furukori N, Saito M, Nakagami T, Kaneda A, Tateishi T, Kaneko S. Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients: a preliminary study. Prog Neuropsychopharmacol Biol Psychiatry. 2006 ; 30: 286-291 (Pubitemid 43288068)